Mono Bar
Main page content

Drug Testing Advisory Board (DTAB)


The Drug Testing Advisory Board (DTAB) shall advise the Assistant Secretary, Substance Abuse and Mental Health Services Administration, based on an ongoing review of the direction, scope, balance, and emphasis of the Agency’s drug testing activities and the drug testing laboratory certification program.

About Drug Testing Advisory Board

The Board shall review the Agency’s program for national laboratory certification for Federal workplace drug testing programs as required by Public Law 100-71 and as described in the Mandatory Guidelines for Federal Workplace Drug Testing Programs. It shall recommend areas for emphasis or de-emphasis, new or changed directions, and mechanisms or approaches for implementing recommendations. Periodically, the Board shall review specific science areas on new drugs of abuse and the methods necessary to detect their presence.

Legislative Authority

Advisory Board Charter

The CSAP Drug Testing Advisory Board (DTAB) provides advice to the Administrator, SAMHSA, based on an ongoing review of the direction, scope, balance, and emphasis of the Agency's drug testing activities and the drug testing laboratory certification program.


The CSAP DTAB is authorized by 42 USC § 217a, (Section 222 of the Public Health Service Act), as amended.

The CSAP DTAB is governed by the provisions of the Federal Advisory Committee Act, as amended, 5 U.S.C., App.,

The CSAP DTAB is also referred to as the DTAB.

Objectives and Scope of Activities

To improve the quality of services for forensic workplace drug testing, assess the science and technology used in drug analyses, improve the quality of related laboratory services and systems for drug testing, generate standards for laboratory certification for federal workplace drug testing programs, and guide national policy in these areas.

Description of Duties

The DTAB provides advice to the Assistant Secretary for Mental Health and Substance Use (Assistant Secretary), Substance Abuse and Mental Health Services Administration (SAMHSA), based on an ongoing review of the direction, scope, balance, and emphasis of the agency's drug testing activities and the drug testing National Laboratory Certification Program (NLCP).

The DTAB shall review the NLCP for federal workplace drug testing programs as required by Public Law 100-71 and as described in the Mandatory Guidelines for Federal Workplace Drug Testing Programs. It shall provide an ongoing review of the science, laws, and policies that impact the Department of Health and Human Services’ (HHS) drug testing activities, including proposed recommendations for areas of emphasis or de-emphasis and mechanisms that will be most effective for implementing any recommendations.

The DTAB shall periodically review specific scientific areas surrounding new drugs of abuse and the methods necessary to detect their presence.

Agency or Official to Whom the Board Reports

The DTAB provides advice to the Assistant Secretary, based on an ongoing review of the direction, scope, and emphasis of the Agency's drug testing activities and the NLCP.


Management and support services shall be provided by the Division of Workplace Programs (DWP), CSAP, SAMHSA.

Estimated Annual Operating Costs and Staff Years

The estimated annual operating costs for the DTAB, to include travel, meetings, federal staff support, and contracting support, is approximately $329,550.00 and 1.3 fulltime equivalents.

Designated Federal Officer

The Director, CSAP, shall designate a SAMHSA staff member to serve as the Designated Federal Officer (DFO) of the DTAB. The DFO will approve or call DTAB meetings and subcommittee meetings, prepare and approve meeting agendas, attend and direct all DTAB meetings and subcommittee meetings, adjourn any meeting when the DFO determines adjournment to be in the public interest, and chair meetings when directed to do so by the official to whom the DTAB reports.

Estimated Number and Frequency of Meetings

The DTAB meetings shall be held approximately four times a year upon request of the Assistant Secretary, or Director of DWP, CSAP. The location of the meetings of the Board shall be subject to the approval of the Director, DWP, CSAP. Meetings shall be open to the public except as determined otherwise by the HHS Secretary (or the designee), in accordance with the Government in the Sunshine Act (5 U.S.C. 552b(c)) and the Federal Advisory Committee Act. Notice of all meetings shall be given to the public. In the event a portion of a meeting is closed to the public, a report shall be prepared which shall contain, at a minimum, a list of members and their business addresses, the DTAB’s functions, dates and places of meetings, and a summary of the DTAB’s activities and recommendations made during the fiscal year.




Unless renewed by appropriate action, the CSAP DTAB will terminate two years from the date the charter is filed.

Membership and Designation

The DTAB shall consist of 10 members appointed by the Assistant Secretary. Of the 10 members, eight shall be recognized as experts in either analytical forensic toxicology, in specimen collection procedures for regulated drug testing programs, or in interpreting drug testing results; one shall represent users of SAMHSA’s certified drug testing laboratories and drug-free workplace programs and processes; and one shall represent individuals tested in federal or federally regulated workplace drug testing programs. These members who are not officers or federal employees (full time or permanent part time) of the United States shall serve as Special Government Employees.

The Assistant Secretary shall appoint non-voting ex officio members, who are officers or employees of the United States. The Assistant Secretary will determine the number of ex officio members on the Board. The individuals appointed should represent a variety of disciplines related to forensic drug testing, such as experience in a forensic drug-testing laboratory, related academic research, toxicological research, the Medical Review Officer (MRO) community, or technical expertise from other government agencies involved with drug testing issues, including military drug testing programs.

The Assistant Secretary shall select either an individual from among the appointed members or an appropriate member of SAMHSA staff to serve as the Chair. If the Chair is a member of SAMHSA staff, the Chair will be a non-voting position. The term of office for the Chair shall be two years.

A quorum for the conduct of DTAB business is the majority (one more than one-half) of the appointed voting membership.

The term of office of a voting member of the DTAB shall be four years. A voting member may serve after the expiration of the member’s term until a successor has been appointed and taken office. If a vacancy occurs in the advisory board among the members, the Assistant Secretary shall make an appointment to fill such vacancy within 90 days from the date the vacancy occurs. Initial appointments shall be made in such a manner as to ensure that the terms of the members do not all expire in the same year. A member who has been appointed for a term of four years may not be reappointed to an advisory committee before two years from the date of expiration of such term of office.

The DWP, CSAP, SAMHSA shall provide orientation and training for new members of the DTAB and shall also provide them with such information and training as may be appropriate for their effective participation in the functions of the Board.


Subcommittees may be established with the approval of the Assistant Secretary. The advice/recommendations of a subcommittee must be deliberated by the parent board. A subcommittee may not provide advice or work products directly to the agency. The Department Committee Management Officer will be notified upon establishment of each subcommittee and will be provided information on its name, membership, function, and estimated frequency of meetings.


Meetings of the DTAB and its subcommittees will be conducted according to the Federal Advisory Committee Act, other applicable laws and Departmental policies. DTAB and subcommittee records will be handled in accordance with General Records Schedule 6.2 of the Federal Advisory Committee Records or other approved agency records disposition schedule. These records will be available for public inspection and copying, subject to the Freedom of Information Act, 5 U.S.C. 552.

Filing Date

June 25, 2022


June 17, 2022



Miriam E. Delphin-Rittmon, Ph.D.
Assistant Secretary for Mental Health and Substance Use

Advisory Board Roster

Lisa S. Davis, M.S.
Social Science Analyst, Senior Toxicology Policy Advisor
Division of Workplace Programs
Center for Substance Abuse Prevention
Substance Abuse and Mental Health Services Administration
Room 16N02C
5600 Fishers Lane
Rockville, MD 20857

Ronald R. Flegel, B.S., MT(ASCP), M.S.
Division of Workplace Programs
Center for Substance Abuse Prevention
Substance Abuse and Mental Health Services Administration
Room 16N01
5600 Fishers Lane
Rockville, MD 20857

David A. Engelhart, Ph.D., D-ABFT-FD, OH
Dr. Engelhart has served as the Laboratory Director for Omega Laboratories, Inc. since 2005 and has over 26 years of experience in forensic toxicology. Omega Laboratories, Inc. is a forensic drug testing facility located in Mogadore Ohio which focuses on the analysis of hair and oral fluid specimens for drug of abuse. His prior employment was with the Office of the Cuyahoga County Coroner located in Cleveland Ohio where he was instrumental in the toxicology laboratory acquiring and maintaining ABFT accreditation.

David received his Bachelor of Science degree in Chemistry from Hiram College and his Doctorate Degree in Chemistry from Case Western Reserve University. He is a board-certified Diplomate of the American Board of Forensic Toxicology in Forensic Drug Toxicology and an inspector for the College of American Pathologists Forensic Drug Testing laboratory accreditation program and a member of the Society of Forensic Toxicologists.

Elizabeth “Libby” B. Stuyt, M.D., CO
Dr. Stuyt is a board-certified Addiction Psychiatrist who has worked in the addiction/behavioral health field since 1990 and was the Medical Director for the Circle Program, a 90-day inpatient treatment program. She works currently as a consultant for Solvista Behavioral Health in Salida, Colorado and educates people nationally on the effects of high potency THC on the developing brain. She is recognized as an expert in interpreting drug test results. Her knowledge of addiction psychiatry and THC is a beneficial addition to DTAB.

Libby earned her Bachelor of Science degree in Biomedicine and a Master of Science degree in Biochemistry from Texas A&M University, and her Doctor of Medicine degree from Texas Tech University.

David K. Roberts, Ph.D., F-ABFT, OR
Dr. David Roberts is a private toxicology consultant with Cascade Toxicology and prior Manager and Responsible Person for Legacy Health, Legacy Laboratory Services in Portland, Oregon, a laboratory certified by the Substance Abuse and Mental Health Services Administration to perform drug testing for specimens regulated by the Federal Workplace Drug Testing Program. He directed the College of American Pathologist Forensic Drug testing as well as the Forensic Specimen Collections services that perform DOT regulated evidential breath alcohol testing.

David earned his Bachelor of Arts degrees in Chemistry and Biology at the University of Missouri at Kansas City and his Ph.D. in Toxicology from Texas A&M University. David is a board-certified Fellow with the American Board of Forensic Toxicology (ABFT) and a member of the Society of Forensic Toxicologists, the American Chemical Society and the Association for Diagnostics and Laboratory Medicine. David is an inspector for the College of American Pathologists Forensic Drug Testing laboratory accreditation program as well as the National Laboratory Certification Program.

E. Lindsey Everson, J.D., TX
Lindsey Everson is a partner with Caldwell Everson P.L.L.C. Mr. Everson has represented some of the largest forensic drug testing laboratories in the United States. He has also provided legal services to third-party administrators and medical review officers in litigation nationwide. Besides providing laboratories and third-party administrators legal services across the country, he also provides consultation and litigation services to other workplace drug testing entities, including employers and collection sites. Lindsey has consulted with both non-certified laboratories and SAMHSA-certified laboratories regarding compliance with National Laboratory Certification Program guidelines and FDT industry standards for forensic workplace drug testing. On behalf of various drug-testing industry entities, he has offered his expertise to Firm clients providing documentary and testimonial evidence in Department of Transportation enforcement proceedings. Lindsey also provides services to Firm clients in proceedings and investigations brought by federal and state agencies with regulatory oversight authority over various FDT entities. Lindsey regularly represents and provides legal advice to Firm clients regarding third-party requests for federal and state-regulated drug testing information and records.

Lindsey received his Bachelor of Arts Degree in Political Science in May 1994 at Texas A&M University and his Juris Doctorate, Cum Laude from the University of Houston Law Center in May 1997 following which he was admitted into the Bar in the U.S. District Court, Eastern, Northern and Southern Districts of Texas.

Dawn M. Hahn, M.B.A., M.T. (ASCP), D-ABFT, KS
Dawn Hahn is the Lab Operations Director and Responsible Person of the Quest Diagnostics Employer Solutions Laboratory in Lenexa, Kansas. Dawn obtained her Bachelor of Arts degree in medical technology from Northwestern College and obtained her M.B.A. from JHU. Prior to joining Quest Diagnostics, Dawn worked as a medical technologist in several clinical laboratories. She joined Home Office Reference Laboratory (HORL) in 1987 performing risk assessment testing for life insurance applicants. HORL eventually became LabONE, which then became Quest Diagnostics in 2005. LabOne obtained its SAMHSA certification in 1994. Dawn played a significant role in the lab obtaining this certification. She has worked for Quest Diagnostics for over 35 years and has held several different roles in the SAMHSA certified laboratory. In her current role, which she has held for over 9 years, she oversees one of the largest workplace drug testing labs in the nation. Quest Diagnostics performs drug testing in urine, oral fluid and hair so Dawn will bring much experience and knowledge to the board as we add alternate matrices to the Federal Program. Dawn has been a consultant for the National Laboratory Certification Program since 2005 performing inspections and serving on the oral fluid lab manual working group. Dawn is a board-certified Diplomate with the American Board of Forensic Toxicology (ABFT) and a member of the Society of Forensic Toxicologists.

Bryan Ruggery, MFS, D-ABFT-FT, VA
Mr. Ruggery presently serves as a Drug Science Specialist with the Drug and Chemical Evaluation Section in the Diversion Control Division of the Drug Enforcement Administration. His responsibilities include providing leadership on technical and scientific matters associated with drugs and toxicology while assisting with drug control scheduling actions, processing exemption applications, evaluating control status inquiries, and analyzing data from the National Forensic Laboratory Information System (NFLIS). He also participates in scientific conferences and inter- and intra- agency meetings concerning drug issues and chemical control. Bryan earned a Bachelor of Science in Applied Forensic Sciences from Mercyhurst College in 2007 and a Master of Forensic Science in Forensic Toxicology from The George Washington University in 2009. He has formerly held several relevant positions. He served as a Medical Technologist at Quest Diagnostics Nichols Institute in Chantilly, VA. He also served as a Forensic Toxicologist with the Office of the Chief Medical Examiner (OCME) in Washington, DC., where he conducted toxicological and drug analysis on Medicolegal Death Investigation, Driving Under the Influence, and Drug Facilitated Crime related casework.

Bryan earned board-certification as a Diplomate with the American Board of Forensic Toxicology (ABFT) and is a full member of the Society of Forensic Toxicologists (SOFT) and an associate member in the Toxicology Section of the American Academy of Forensic Sciences (AAFS).

Michael Grommes, D-ABFT-FD, AZ
Michael Grommes has been a Forensic Toxicologist for 28 years. He is a 1994 graduate of Arizona State University with a B.S. in Chemistry. In 2006, he also completed the Degreed Certificate Program in Forensic Toxicology from the University of Florida. Mike is a full member of the Society of Forensic Toxicologists (SOFT), a member of the California Association of Toxicologists (CAT) and a Diplomate of the American Board of Forensic Toxicology (D-ABFT-FD). He has been certified by the Arizona Department of Public Safety as an Arizona Licensed Alcohol Analyst since 1994 . Michael has also been an NLCP Federal Laboratory Inspector since 2013. He is the toxicologist for Blood Alcohol Testing & Consulting, LLC since 1999 and is the Laboratory Director/RP and co-owner of Desert Tox, LLC, Arizona’s only SAMSHA/HHS/DOT certified laboratory, which opened in 2017. He has testified in hundreds of cases in various courts throughout the State of Arizona on drug and alcohol related cases. He has also been an Adjunct Professor of Forensic Toxicology at Arizona State University since January 2022.

Carl Christensen, M.D., MI
Carl Christensen, M.D. has been certified as a Medical Review Officer (MRO) since 2005; he currently works as an MRO reviewing DOT, non-DOT and healthcare professional drug testing results for Vault Workforce. He has just been appointed to the MROCC Exam Development Committee. He has been an addiction provider for the Michigan’s Physician Monitoring Program (the Michigan Health Professional Recovery Program) since 2009; the Chair of the oversight committee until 2013; and the current Medical Director since 2014. He serves as an expert witness for the DEA and the US Attorney’s Office and local law enforcement and develops Continuing Medical Education for the Michigan State Medical Society in pain and addiction management. Dr. Christensen is also a Clinical Associate Professor of Psychiatry and Obstetrics and Gynecology at the Wayne State University (WSU) School of Medicine in Detroit. While an Associate Professor, he served as the Medical Director for the Substance Abuse Research Division at WSU; the Medical Director of the Eleonore Hutzel Recovery Center, specializing in the treatment of pregnant addicted women; the Associate Residency Director and Medical Clerkship Director in the Department of OB Gyn at the Detroit Medical Center. He is Board Certified in addiction medicine and obstetrics and gynecology and a Distinguished Fellow of the American Society of Addiction Medicine.

Samantha S. Tolliver, Ph.D., Washington DC
Samantha S. Tolliver, Ph.D., is the Chief Toxicologist at the Washington, DC Office of the Chief Medical Examiner and has been employed there since 2014. Her eighteen years of toxicology experience include postmortem, driving under the influence, drug facilitated crime, pre/post-exposure, and workplace drug testing. Her testimony experience encompasses civil (family law) and criminal cases within the States of Texas, Massachusetts, and the District of Columbia. Dr. Tolliver holds a Bachelor of Science in Chemistry from West Virginia State University. She earned both her Master of Science in Forensic Science and a Doctorate in Chemistry from Florida International University. She is certified in toxicology by the National Registry of Certified Chemists. Dr. Tolliver has made scientific presentations at the Drug & Alcohol Testing Industry Association, the American Academy of Forensic Scientists, and the Society of Forensic Toxicologists (SOFT). Dr. Tolliver is an active member of SOFT, and the American Academy of Forensic Sciences.

Bonnie A. Droter, Washington, DC
Ms. Bonnie Droter currently serves as the Drug-free Workplace Program Manager with the U.S. Department of Agriculture (USDA) and has occupied this position since October 2017. Ms. Droter has 18 years in federal service spread between USDA and the Department of Army’s Walter Reed Army Medical Center and has served as a Contracting Officer Representative since May 2013. In her current role, she is charged with ensuring proper compliance with the Department’s Drug-Free Workplace Program and provides leadership and guidance for 14 Agency Drug Testing Liaisons. As part of the Office of Human Resources Management, she provides support services to 29 USDA agencies and staff offices with approximately 94,000 federal personnel by assisting in the execution of their role in the departmental Drug-Free Workplace program. Management of this program includes managing departmental funding as well as ongoing program compliance review, advice and counsel, and assisting agencies with third party random testing selection processing; scheduling, tracking, and reporting multiple types of testing; applicant notification; Agency Drug Testing Liaison training; and coordination of on-site collection services. The USDA processes an average of 3,000 drug tests annually, based on years 2017-2023 collection totals ranging from around 550 during the pandemic up to over 7,600 in 2023. She is considered the subject matter expert in Federal Workplace Drug Testing policy and how it applies to the federal employees at the USDA.

Brian Zaleski
Specialist – Fitness for Duty/Access Authorization
Office of Nuclear Security and Incident Response
U.S. Nuclear Regulatory Commission
Mail Stop OWF-02H07
Washington, DC 20555-0001

Joseph Kotarek
Branch Chief, Toxicology
Food and Drug Administration, Office of In Vitro Diagnostics and Radiological Health (OIR)
Division of Chemistry and Toxicology Devices (OHT7)
WO66 RM4643
10903 New Hampshire Ave.
Silver Spring, MD, 20993-0002

Bohdan Baczara
Deputy Director, Office of Drug and Alcohol Policy and Compliance
Office of Drug and Alcohol Policy and Compliance
U.S. Department of Transportation
1200 New Jersey Avenue, SE
Washington, DC 20590

Nomination for Membership

Nomination for Membership

The DTAB membership includes individuals who represent legislatively mandated categories and serve 4-year terms. The membership criteria is described in the DTAB Charter, under the section ‘Membership and Designation’. DTAB accepts nominations on a rolling basis and will keep nomination information on file for consideration to fill any vacancies that may occur for up to 3 years. Interested persons who meet the membership criteria can send their CV/resume with a brief statement of intent, to the SAMHSA National Advisory Councils Resource Mailbox with subject line “DTAB Nomination” to:

Last Updated
Last Updated: 05/20/2024
Last Updated